Drugs in ATC Class D07AA

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Up to D07A - CORTICOSTEROIDS, PLAIN

Drugs in ATC Class: D07AA - Corticosteroids, weak (group I)

Tradename	Generic Name
DEPO-MEDROL	methylprednisolone acetate
M-PREDROL	methylprednisolone acetate
MEDROL	methylprednisolone
MEDROL	methylprednisolone acetate
METHYLPREDNISOLONE	methylprednisolone
METHYLPREDNISOLONE ACETATE	methylprednisolone acetate

D07AA Market Analysis and Financial Projection

The ATC class D07AA encompasses weak corticosteroids (group I) used primarily in dermatology, including methylprednisolone, hydrocortisone, and prednisolone. These agents are critical in treating inflammatory skin conditions like eczema and dermatitis.

---

Market Dynamics

Growth Drivers

• Rising Skin Disease Prevalence:
  The global topical corticosteroids market is projected to reach USD 10.5 billion by 2032 (CAGR 6.6%)[14], driven by increasing cases of inflammatory skin disorders.

  • Over 31 million people in the U.S. had eczema in 2020[13], with similar trends globally.
  • North America dominates with 40% market share due to advanced healthcare infrastructure[7].

• Innovation in Formulations:
  Companies like Eli Lilly are advancing R&D, combining corticosteroids with biologics (e.g., Lebrikizumab for atopic dermatitis)[13].

• Pandemic Impact:
  COVID-19 boosted demand for corticosteroid-based treatments, including nasal sprays and systemic therapies[13][14].

Market Segmentation

Segment	Key Insights
By Type	Hydrocortisone leads with extensive use due to its safety profile[15].
By Application	Adults account for 80% of corticosteroid eyedrop use[7].
Distribution	Hospital pharmacies hold 45% market share, reflecting prescription reliance[7].

Regional Trends

• Asia-Pacific: Rapid growth due to improving healthcare access and high patient volumes[7].
• Europe: Focus on advanced formulations and favorable reimbursement policies[13].

---

Patent Landscape

Generics Dominance

• Most D07AA drugs (e.g., hydrocortisone) are off-patent, leading to generic dominance. Hydrocortisone’s patents expired in most jurisdictions[15].
• Methylprednisolone acetate is available from 13 manufacturers, including Pfizer and Teva[6].

Innovation in Synthesis

• Recent patents focus on efficient corticosteroid synthesis. For example:
  • A single-step process to produce 17-desoxy corticosteroids with halogens (e.g., Diflucortolone, Desoximetasone)[9].
  • Improved selectivity and reduced side effects through novel chemical methods[9].

Regulatory and Pipeline Activity

• Therapeutic Alternatives: The WHO Essential Medicines List (EML) permits substitutions within D07AA for dermatological use[15].
• Pipeline Developments:
  • Lebrikizumab + TCS (Phase 3 trial for atopic dermatitis)[13].
  • Ophthalmic formulations targeting allergic eye diseases (e.g., dexamethasone eyedrops)[7].

---

Challenges

• Cost and Accessibility: High R&D costs and uneven healthcare access hinder growth in emerging economies[13].
• Side Effects: Long-term use risks (e.g., skin atrophy) drive demand for safer alternatives[14].
• Regulatory Hurdles: Complex approval processes delay new formulations[14].

---

Key Takeaways

• The D07AA market is stable but competitive, with generics dominating.
• Innovation focuses on combination therapies and improved delivery systems.
• North America and Asia-Pacific are pivotal for future growth, driven by rising skin disease burdens and healthcare investments.

"The process of the present invention provides high region-selectivity of hydroxyl removal at position 17 of the corticosteroid while one or more halogen groups remain intact." – [Justia Patents][9]

References

1. https://en.wikipedia.org/wiki/ATC_code_D07
2. https://en.wikipedia.org/wiki/Anatomical_Therapeutic_Chemical_Classification_System
3. https://www.gminsights.com/industry-analysis/corticosteroids-market
4. https://go.drugbank.com/drugs/DB00741
5. https://go.drugbank.com/drugs/DB00959
6. https://www.drugpatentwatch.com/p/generic-api/METHYLPREDNISOLONE+ACETATE
7. https://marketresearch.biz/report/corticosteroid-eyedrops-market/
8. https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=D07AA
9. https://patents.justia.com/patent/10112970
10. https://www.globenewswire.com/news-release/2024/12/12/2996447/0/en/Parkinson-s-Disease-Market-is-Expected-to-Showcase-a-Significant-Growth-at-a-CAGR-of-5-8-During-the-Study-Period-2020-2034-DelveInsight.html
11. https://go.drugbank.com/drugs/DB00860
12. https://catalogues.ema.europa.eu/sites/default/files/document_files/B026%20PASS_Redacted%20(1).pdf
13. https://www.databridgemarketresearch.com/reports/global-topical-corticosteroids-market
14. https://www.marketresearchfuture.com/reports/topical-corticosteroids-market/market-size
15. https://list.essentialmeds.org/recommendations/194